Cargando…
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease
BACKGROUND AND AIMS: Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of Crohn’s disease and may serve as a potential biomarker. A phase 2 trial was conducted to examine the efficacy and safety of the anti-MMP9 antibody andecaliximab [GS-5745] in patients with moderately to severe...
Autores principales: | Schreiber, Stefan, Siegel, Corey A, Friedenberg, Keith A, Younes, Ziad H, Seidler, Ursula, Bhandari, Bal R, Wang, Ke, Wendt, Emily, McKevitt, Matt, Zhao, Sally, Sundy, John S, Lee, Scott D, Loftus, Edward V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113705/ https://www.ncbi.nlm.nih.gov/pubmed/29846530 http://dx.doi.org/10.1093/ecco-jcc/jjy070 |
Ejemplares similares
-
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease
por: Sandborn, William J, et al.
Publicado: (2018) -
A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
por: Ooki, Akira, et al.
Publicado: (2022) -
Configuring the patient as clinical research subject in the UK national health service
por: Adams, Mary, et al.
Publicado: (2015) -
The Possibilities and Limits of “Co-producing” Research
por: Paylor, Jonathan, et al.
Publicado: (2019) -
A Case of Difficult Arterial Cannulation: Is Intra-Arterial Blood Pressure Monitoring an Absolute Requirement for Paediatric Liver Transplantation?
por: McKevitt, Helen, et al.
Publicado: (2023)